Immunotherapy of prostate cancer
Authors:
Jiřina Bartůňková 1; Radek Špíšek 1; Michal Podrazil 1; Ladislav Jarolím 2
Authors‘ workplace:
Ústav imunologie 2. LF UK a FN Motol, Praha
1; Urologická klinika 2. LF UK a FN Motol, Praha
2
Published in:
Ces Urol 2014; 18(4): 273-278
Category:
Review article
Overview
Immunotherapy has become an increasingly appealing therapeutic strategy for cancer patients. Tumorigenesis a very represents a complex, multistage process. Tumour cells are a heterogeneous population which is developing in the context of a microenvironment of non-tumour cells and tisues, thus forming a complex „ecosystem“. In the early stages of tumour development, the immune system is capable of controlling the cell growth. With advanced tumour growth, immune mechanisms become more or less paralysed and frequently even exert a promoting effect on tumour cell proliferation. In order to be successful, anticancer therapy must take into consideration all the comprehensive aspects of interaction of the immune system and tumour cells, including the microenvironment. This communication discussess current options in immunotherapy of prostate cancer with agents that have advanced into phase III clinical trials.
Key words:
immunotherapy, prostate cancer, clinical trials.
Sources
1. http://globocan.iarc.fr.
2. http://www.uroweb.cz/
3. Mottet N, Bastian PJ, Bellmunt J, et al. Guidelines on Prostate Cancer. European Association of Urology 2014. www.uroweb.org/gls/pdf/09%20Prostate%20Cancer_LRLV2.pdf
4. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351(15): 1502–1512.
5. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329–360.
6. Dimonte G. A cell kinetics model for prostate cancer and its application to clinical data and individual patients. J Theor Biol 2010; 264(2): 420–442.
7. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363(5): 411–422.
8. Higano C, et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer. ASCO 2009 Genitourinary Cancer Symposium, Orlando, FL, USA, 2009; abstrakt LBA150.
9. Small E, et al. A Phase III trial of GVAX Immunotherapy for Prostate Cancer in Combination with Docetaxel versus Docetaxel Plus Prednisone in Symptomatic, Castration-Resistant Prostate Cancer. ASCO 2009 Genitourinary Cancer Symposium, Orlando, FL, USA, 2009; abstrakt 7.
10. van den Eertwegh AJM, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13: 509–517.
11. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol 2010; 28: 1099–1105.
12. Steinman RM. Lasker Basic Medical Research Award. Dendritic cells: versatile controllers of the immune system. Nat Med 2007; 13(10): 1155–1159.
13. Galluzi, Senovilla L, Vacchelli E, et al. Trial watch: Dendritic cell-base interventions for cancer therapy. Oncoimmunology 2012; 1(7): 1111–1134.
14. Jarolím L, Špíšek R, Podrazil M, et al. Long-term immunotherapy by dendritic-cells based vaccine in patiens with PSA recurrent prostate cancer. European Urology, Supplements 2014; 13(1)e872, 29th Annual EAU Congress, Stockholm, 11. 4. to 15. 4. 2014.
15. Podrazil M, Rožková D, Fučíková J, et al. Combined chemoimmunotherapy of castrate-resistant prostate cancer with dendritic-cell based vaccine DCVAC/Pca, CIMT 2014, Abstracts, 12th Annual Meeting, 6. 5. to 8. 5. 2014, Mainz, Germany.
16. Hodi FS, O’Day SJ, McDermott DF, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. NEJM 2010; 363: 711–723.
17. Tisková zpráva Bristol-Myers Squibb ze dne 12. 9. 2013. http://news.bms.com/press-release/rd-news/bristol-myers-squibb-reports-results-phase-3-trial-yervoy-ipilimumab-previousl.
18. Fučíková J, Králíková P, Fialová A, et al. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 2011; 71(14): 4821–4833.
Labels
Paediatric urologist Nephrology UrologyArticle was published in
Czech Urology
2014 Issue 4
Most read in this issue
- Extracoporeal shock wave lithotripsy in current urological practice
- Use of multiparametric magnetic resonance imaging and comparison with other modern imaging methods in the preoperative diagnosis of prostate cancer
- Autonomic dysreflexia in patient after spinal cord injury
- Evaluation of erectile dysfunction after robotic assisted radical prostatectomy